Dr. Patrick P. Lin, MD

Dr. Lin practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Lin's NPI, 1144325747, was assigned on September 14, 2006. Dr. Lin graduated from Stanford University School Of Medicine in 1990. Dr. Lin holds Texas license K6102.

Dr. Lin's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Lin's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lin practices. Vendor and product names are available with a free account.

Orthopaedic surgery is Dr. Lin's primary specialty in the NPI Registry, under taxonomy code 207X00000X. Dr. Lin is board certified in orthopaedic surgery by the American Board of Orthopaedic Surgery. Dmand AI has Dr. Lin's licenses on file in 10 states: Texas, Florida, Washington, Arizona, Georgia, Mississippi, Tennessee, Alabama, Louisiana and Oklahoma.

Dmand AI lists broken or dislocated ankle/ or foot, hip replacement, joint cyst, joint pain, knee replacement, muscle pain, fibromyalgia, and limb pain, orthopedic surgery of arms and legs and pelvic and hip fracture among the conditions Dr. Lin treats.

CMS data shows 116 Medicare services from Dr. Lin across 2 procedure codes in 2024, all of them office visits, for 128 Medicare patients. Medicare paid $4,788 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 128 Medicare patients who saw Dr. Lin in 2024. The largest group is 65 to 74, with 71 patients. 75% of them have high blood pressure, and 73% have high cholesterol. Their average risk score is 2.51, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lin's median patient age at 68, with 53% women.

In 2024, Dr. Lin wrote 16 Medicare Part D claims. 100% of them were for generic drugs. CMS names the drug for 15 of them, across 1 drug with 11 or more claims each, at $270 in total drug cost. In 2019, CMS named 13 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Lin for performance year 2024, reported as part of a group. Dr. Lin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Lin as offering telehealth.

Knee replacement: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 87 papers to Dr. Lin, published from 2006 to 2021. 2015 was the busiest year, with 7. The most frequent topics are Bone Neoplasms, Sarcoma and Osteosarcoma. Dr. Lin has published most often in Clin Orthop Relat Res. Dr. Lin's most frequent co-authors are Valerae O. Lewis, MD, Shreyaskumar R. Patel and Robert S. Benjamin, MD.

CMS Open Payments shows 63 general payments to Dr. Lin from 9 drug and device companies from 2016 to 2025. Honoraria make up the largest share, 38% of the total. Musculoskeletal Transplant Foundation Inc. paid the most, $11,681.

Dr. Lin graduated from Stanford University School Of Medicine in 1990.

Dr. Lin is in network with 7 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. POS plans come from the most carriers, 5. Check the plan with the practice before a visit.